Physician profile
William Sera
NPI 1679747646
$4,360.43
in general payments reported to CMS, 2019-2025
24 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $196 · 2023: $1,263 · 2024: $1,462 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,865 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,864.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $841.24 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.25 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $454.48 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $426.05 | 2023-2025 | |
| Dexcom, INC. | $385.24 | 2022-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $335.77 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $270.94 | 2023-2025 | Evenity, Prolia, Repatha |
| Xeris Pharmaceuticals, INC. | $231.96 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $174.07 | 2022-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $158.27 | 2024-2025 | Isturisa, Signifor Lar |
| Acella Pharmaceuticals, LLC | $108.44 | 2024-2025 | NP Thyroid 60 |
| Insulet Corporation | $61.95 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $59.40 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $56.04 | 2022-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $48.66 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $34.55 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $31.02 | 2024 | Strensiq |
| Avion Pharmaceuticals | $29.67 | 2023-2024 | NP Thyroid 60 |
| Abbott Laboratories | $22.91 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $22.76 | 2024 | Unithroid |
| Abbvie INC. | $20.27 | 2025 | |
| Horizon Therapeutics Plc | $19.97 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $18.07 | 2025 | Yorvipath |
| Averitas Pharma INC. | $17.45 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.